Special Issue

Microparticle-Based Vaccines

Message from the Guest Editor

This special issue will highlight and bring out the state of the art in the development of microparticle-based vaccines, a transcendent approach for vaccine design not only against infectious diseases, but also for stimulating immune responses against cancer. Particulate carriers offer several attributes for use as vaccine delivery systems. First, microparticles can mimic the size of the pathogens that the immune system has evolved to combat and, consequently, they are efficiently better recognized and internalized by antigen presenting cells, facilitating the uptake of the antigens (or genetic material) carried. In addition, these particulate systems can present multiple copies of the antigens, not only on their surface but also forming part of the internal particle structure, protecting the antigens from degradation and increasing the antigen persistence. As a guest editor of this Special Issue, I invite you to submit research and review articles related to this special edition, which will help researchers in the vaccinology field to develop and improve new vaccine strategies based in these particulate platforms.

Guest Editor

Dr. Alejandro Marin-Lopez
Department of Internal Medicine, Section of Infectious Diseases, School of Medicine, Yale University, New Haven, CT, USA

Deadline for manuscript submissions

closed (15 August 2022)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/90248

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI